X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AB126 is an unmodified neural-derived exosome with an innate ability to traverse the blood brain barrier and shows evidence of anti-inflammatory and neuroprotective properties. It is being evaluated for the treatment of acute ischemic stroke.
Lead Product(s): AB126
Therapeutic Area: Neurology Product Name: AB126
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
AB126, an unmodified exosome derived from neural stem cells, has broad therapeutic, which is investigated in superoxide dismutase 1 amyotrophic lateral sclerosis (ALS) mouse model.
Lead Product(s): AB126
Therapeutic Area: Neurology Product Name: AB126
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
AB126 is an unmodified neural-derived exosome with the innate ability to cross the blood-brain barrier. AB126 is designed to provide potential therapeutic benefit in its native form for multiple different neurological indications.
Lead Product(s): AB126
Therapeutic Area: Neurology Product Name: AB126
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
AB126 are allogenic neural exosomes derived from neural stem cells, is highly effective at crossing the blood/brain barrier – so it can carry other molecules across.
Lead Product(s): AB126
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AB126
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Georgia Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
The award will support advancement of AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI).
Lead Product(s): AB126
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AB126
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
